{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:39:33Z","timestamp":1776440373974,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2013-41945-R"],"award-info":[{"award-number":["SAF2013-41945-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBER de Enfermedades Raras"},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006541","name":"Consejer\u00eda de Sanidad, Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2011\/BMD-2402"],"award-info":[{"award-number":["S2011\/BMD-2402"]}],"id":[{"id":"10.13039\/501100006541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12967-017-1136-5","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T01:07:20Z","timestamp":1486688840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis"],"prefix":"10.1186","volume":"15","author":[{"given":"Fulvio","family":"Santacatterina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"S\u00e1nchez-Arag\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Catal\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gl\u00f2ria","family":"Garrabou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Nu\u00f1ez","family":"de Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Cardellach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Cuezva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"1136_CR2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734\u201347.","journal-title":"N Engl J Med"},{"key":"1136_CR3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"1136_CR4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","volume":"28","author":"FL Mastaglia","year":"2002","unstructured":"Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002;28:723\u201341.","journal-title":"Rheum Dis Clin North Am"},{"key":"1136_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.autrev.2014.01.016","volume":"13","author":"M Catalan","year":"2014","unstructured":"Catalan M, Selva-O\u2019Callaghan A, Grau JM. Diagnosis and classification of sporadic inclusion body myositis (sIBM). Autoimmun Rev. 2014;13:363\u20136.","journal-title":"Autoimmun Rev"},{"key":"1136_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molonc.2010.09.003","volume":"4","author":"C Mueller","year":"2010","unstructured":"Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol. 2010;4:461\u201381.","journal-title":"Mol Oncol"},{"key":"1136_CR7","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5:2512\u201321.","journal-title":"Mol Cancer Ther"},{"key":"1136_CR8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/nbt910","volume":"21","author":"GA Michaud","year":"2003","unstructured":"Michaud GA, Salcius M, Zhou F, Bangham R, Bonin J, Guo H, et al. Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol. 2003;21:1509\u201312.","journal-title":"Nat Biotechnol"},{"key":"1136_CR9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature02627","volume":"429","author":"RL Strausberg","year":"2004","unstructured":"Strausberg RL, Simpson AJ, Old LJ, Riggins GJ. Oncogenomics and the development of new cancer therapies. Nature. 2004;429:469\u201374.","journal-title":"Nature"},{"key":"1136_CR10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2011.07.022","volume":"311","author":"M Aldea","year":"2011","unstructured":"Aldea M, Clofent J, Nunez de Arenas C, Chamorro M, Velasco M, Berrendero JR, et al. Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer. Cancer Lett. 2011;311:210\u20138.","journal-title":"Cancer Lett"},{"key":"1136_CR11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1593\/tlo.09106","volume":"2","author":"P Acebo","year":"2009","unstructured":"Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, et al. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol. 2009;2:138\u201345.","journal-title":"Transl Oncol"},{"key":"1136_CR12","doi-asserted-by":"crossref","first-page":"25308","DOI":"10.1074\/jbc.M110.146480","volume":"285","author":"L Sanchez-Cenizo","year":"2010","unstructured":"Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M, et al. Up-regulation of the ATPase Inhibitory Factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem. 2010;285:25308\u201313.","journal-title":"J Biol Chem"},{"key":"1136_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12967-015-0424-1","volume":"13","author":"F Santacatterina","year":"2015","unstructured":"Santacatterina F, Chamorro M, Nu\u00f1ez de Arenas C, Navarro C, Martin MA, Cuezva JM, et al. Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases. J Trans Med. 2015;13:65.","journal-title":"J Trans Med"},{"key":"1136_CR14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bbadis.2009.01.006","volume":"1792","author":"JM Cuezva","year":"2009","unstructured":"Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M. The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta. 2009;1792:1145\u201358.","journal-title":"Biochim Biophys Acta"},{"key":"1136_CR15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.15252\/msb.20145746","volume":"10","author":"K Yizhak","year":"2014","unstructured":"Yizhak K, Le Devedec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, et al. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol Syst Biol. 2014;10:744.","journal-title":"Mol Syst Biol"},{"key":"1136_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1699-258X(08)72464-1","volume":"4","author":"OCA Selva","year":"2008","unstructured":"Selva OCA, Trallero AE. Inflammatory myopathies. Dermatomyositis, polymyositis, and inclusion body myositis. Reumatol Clin. 2008;4:197\u2013206.","journal-title":"Reumatol Clin"},{"key":"1136_CR17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","volume":"48","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48:607\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"1136_CR18","first-page":"607","volume":"65","author":"O Benveniste","year":"2015","unstructured":"Benveniste O. Acquired inflammatory myopathies: interest of specific autoantibodies for their classification. Rev Prat. 2015;65:607\u201312.","journal-title":"Rev Prat"},{"key":"1136_CR19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/508158a","volume":"508","author":"H Ledford","year":"2014","unstructured":"Ledford H. Metabolic quirks yield tumour hope. Nature. 2014;508:158\u20139.","journal-title":"Nature"},{"key":"1136_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-62703-311-4_13","volume":"986","author":"MI Sereni","year":"2013","unstructured":"Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ. Reverse phase protein microarrays and their utility in drug development. Methods Mol Biol. 2013;986:187\u2013214.","journal-title":"Methods Mol Biol"},{"key":"1136_CR21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487\u201398.","journal-title":"N Engl J Med"},{"key":"1136_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/B978-0-7020-4086-3.00032-1","volume":"119","author":"AJ Kooi van der","year":"2014","unstructured":"van der Kooi AJ, de Visser M. Idiopathic inflammatory myopathies. Handb Clin Neurol. 2014;119:495\u2013512.","journal-title":"Handb Clin Neurol"},{"key":"1136_CR23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.21230","volume":"39","author":"KC Parker","year":"2009","unstructured":"Parker KC, Kong SW, Walsh RJ, Salajegheh M, Moghadaszadeh B, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve. 2009;39:739\u201353.","journal-title":"Muscle Nerve"},{"key":"1136_CR24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","volume":"326","author":"B Sigurgeirsson","year":"1992","unstructured":"Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363\u20137.","journal-title":"N Engl J Med"},{"key":"1136_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96\u2013100.","journal-title":"Lancet"},{"key":"1136_CR26","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","volume":"12","author":"YJ Chen","year":"2010","unstructured":"Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12:R70.","journal-title":"Arthritis Res Ther"},{"key":"1136_CR27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"1136_CR28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0021-9258(19)45620-2","volume":"247","author":"JL Robinson","year":"1972","unstructured":"Robinson JL, Rose IA. The proton transfer reactions of muscle pyruvate kinase. J Biol Chem. 1972;247:1096\u2013105.","journal-title":"J Biol Chem"},{"key":"1136_CR29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0888-7543(88)90112-7","volume":"2","author":"H Tsutsumi","year":"1988","unstructured":"Tsutsumi H, Tani K, Fujii H, Miwa S. Expression of L- and M-type pyruvate kinase in human tissues. Genomics. 1988;2:86\u20139.","journal-title":"Genomics"},{"key":"1136_CR30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.biocel.2010.02.005","volume":"43","author":"S Mazurek","year":"2011","unstructured":"Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969\u201380.","journal-title":"Int J Biochem Cell Biol"},{"key":"1136_CR31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","volume":"8","author":"D Anastasiou","year":"2012","unstructured":"Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839\u201347.","journal-title":"Nat Chem Biol"},{"key":"1136_CR32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chembiol.2014.08.007","volume":"21","author":"B DeLaBarre","year":"2014","unstructured":"DeLaBarre B, Hurov J, Cianchetta G, Murray S, Dang L. Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem Biol. 2014;21:1143\u201361.","journal-title":"Chem Biol"},{"key":"1136_CR33","doi-asserted-by":"crossref","first-page":"ra73","DOI":"10.1126\/scisignal.2000431","volume":"2","author":"T Hitosugi","year":"2009","unstructured":"Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2:ra73.","journal-title":"Sci Signal"},{"key":"1136_CR34","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.febslet.2014.04.011","volume":"588","author":"MA Iqbal","year":"2014","unstructured":"Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RN. Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett. 2014;588:2685\u201392.","journal-title":"FEBS Lett"},{"key":"1136_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1073\/pnas.1311249111","volume":"111","author":"HJ Wang","year":"2014","unstructured":"Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin YS, Yang SF, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc Natl Acad Sci USA. 2014;111:279\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1136_CR36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo W, Hu H, Chang R, Zhong J, Knabel M, O\u2019Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732\u201344.","journal-title":"Cell"},{"key":"1136_CR37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","volume":"480","author":"W Yang","year":"2011","unstructured":"Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480:118\u201322.","journal-title":"Nature"},{"key":"1136_CR38","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1038\/oncsis.2013.9","volume":"2","author":"M Sanchez-Arago","year":"2013","unstructured":"Sanchez-Arago M, Formentini L, Martinez-Reyes I, Garcia-Bermudez J, Santacatterina F, Sanchez-Cenizo L, et al. Expression, regulation and clinical relevance of the ATPase Inhibitory Factor 1 in human cancers. Oncogenesis. 2013;2:e46.","journal-title":"Oncogenesis"},{"key":"1136_CR39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2012.01.008","volume":"45","author":"L Formentini","year":"2012","unstructured":"Formentini L, S\u00e1nchez-Arag\u00f3 M, S\u00e1nchez-Cenizo L, Cuezva JM. The mitochondrial ATPase Inhibitory Factor 1 (IF1) triggers a ROS-mediated retrograde pro-survival and proliferative response. Mol Cell. 2012;45:731\u201342.","journal-title":"Mol Cell"},{"key":"1136_CR40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.6357","volume":"7","author":"F Santacatterina","year":"2016","unstructured":"Santacatterina F, Sanchez-Cenizo L, Formentini L, Mobasher MA, Casas E, Rueda CB, et al. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase Inhibitory Factor 1 induces a tumor-promoter metabolic state. Oncotarget. 2016;7:490\u2013508.","journal-title":"Oncotarget"},{"key":"1136_CR41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/hep.27312","volume":"60","author":"R Song","year":"2014","unstructured":"Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase Inhibitory Factor 1 and NF-kappaB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60:1659\u201373.","journal-title":"Hepatology"},{"key":"1136_CR42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000439027","volume":"82","author":"S Wei","year":"2015","unstructured":"Wei S, Fukuhara H, Kawada C, Kurabayashi A, Furihata M, Ogura S, et al. Silencing of ATPase Inhibitory Factor 1 inhibits cell growth via cell cycle arrest in bladder cancer. Pathobiology. 2015;82:224\u201332.","journal-title":"Pathobiology"},{"key":"1136_CR43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.biopha.2014.12.036","volume":"70","author":"T Yin","year":"2015","unstructured":"Yin T, Lu L, Xiong Z, Wei S, Cui D. ATPase Inhibitory Factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells. Biomed Pharmacother. 2015;70:90\u20136.","journal-title":"Biomed Pharmacother"},{"key":"1136_CR44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3892\/ol.2015.3548","volume":"10","author":"J Wu","year":"2015","unstructured":"Wu J, Shan Q, Li P, Wu Y, Xie J, Wang X. ATPase Inhibitory Factor 1 is a potential prognostic marker for the migration and invasion of glioma. Oncol Lett. 2015;10:2075\u201380.","journal-title":"Oncol Lett"},{"key":"1136_CR45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbabio.2016.02.004","volume":"1857","author":"J Garcia-Bermudez","year":"2016","unstructured":"Garcia-Bermudez J, Cuezva JM. The ATPase Inhibitory Factor 1 (IF1): a master regulator of energy metabolism and of cell survival. Biochim Biophys Acta. 2016;1857:1167\u201382.","journal-title":"Biochim Biophys Acta"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T22:44:39Z","timestamp":1658616279000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1136-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1136-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]},"article-number":"29"}}